SofWave Medical Earnings Call Transcripts
Fiscal Year 2026
-
Q3 2026 revenue rose 35% YoY to $28.5M, with utilization fees contributing 47% of sales and gross margin at 76.7%. China approval and a 70-system opening order support expansion, alongside plans to grow U.S. sales and international reach.
-
Q3 2026 revenue rose 35% YoY, with utilization up 60% and contributing 47% of revenue. China approval and a 70-system order support expansion, while management sees further international growth and long-term margin potential.
-
Q2 2026 revenue rose 43% YoY to $29.96M, while usage fees grew 52% to $13.9M. China launch is slated for Q4 2026, and management expects 2027 to be an exceptional commercial year for Pure Impact VIP.
-
Q2 revenue hit a record $29.96M, up 43% YoY, with 76.5% gross margin and adjusted operating income up 41%. Usage fees and utilization accelerated; H2 priorities include productivity, next-generation development, and potential China commercialization subject to approval.
-
Strong demand for non-invasive skin rejuvenation and a unique business model have driven rapid growth, with over 40% of revenue now recurring and nearly 100% gross margin on consumables. Geographic expansion, new indications, and a robust IP portfolio position the company for continued high double-digit growth.
Fiscal Year 2025
-
Revenue grew 58% year-over-year in Q4 and 47% for the full year, with ongoing usage fees now 43% of total revenue. Achieved IFRS profitability, strong gross margins, and expanding global footprint, driven by demand for regenerative, non-invasive treatments.
-
Record Q3 revenue and strong profitability were driven by recurring virtual consumable sales and global expansion. Innovative non-invasive technology, high customer satisfaction, and a growing GLP-1 patient segment are fueling demand and supporting a robust financial outlook.
-
Exceptional revenue growth and profitability have been achieved, driven by proprietary technology, recurring revenue, and global expansion. Demand for non-invasive treatments is rising, with strong brand awareness and high provider satisfaction supporting continued growth.
-
Record revenue growth, strong recurring revenue from virtual consumables, and high profitability mark recent performance. Product innovation and regulatory wins, especially in Japan, support global expansion, while GLP-1 trends drive demand for skin tightening and muscle toning.
-
Q3 2025 saw 56% year-over-year revenue growth to $21.1 million, with strong recurring revenue and a 73.7% gross margin. Brand momentum, digital engagement, and regulatory tailwinds are driving adoption, while the company remains resilient amid macroeconomic and competitive challenges.
-
Q2 2025 saw 43% revenue growth year-over-year, record net income, and strong recurring revenue. Gross margin exceeded 75%, with robust cash generation and expanding global presence. Demand for skin tightening and volumization remains high despite macroeconomic headwinds.
-
Aesthetic device sales are accelerating, driven by patented non-invasive ultrasound technology, a recurring revenue model, and strong digital marketing. Recent FDA clearances and global expansion, especially in Asia, support continued growth and profitability.
-
Q1 2025 revenue grew 26% year-over-year to $16.7 million, with recurring pulses up 49%. Brand awareness and demand surged, aided by organic celebrity endorsements and new market entries, notably Japan. Non-GAAP margins reached 76.4%.
-
Aesthetic device demand is surging, fueled by GLP-1 weight loss trends and global expansion, with high ROI and strong brand engagement. The company’s patented technology, recurring revenue model, and proven leadership support rapid growth and profitability.
-
Aesthetic device provider leverages proprietary ultrasound technology and a frictionless business model to drive rapid revenue growth, high margins, and global expansion. Strong brand awareness, digital marketing, and product innovation support continued market share gains and profitability.
Fiscal Year 2024
-
Non-invasive ultrasound technology and a frictionless business model are fueling double-digit growth, high customer ROI, and strong recurring revenue. Global expansion continues, with a focus on brand awareness, product innovation, and margin improvement.
-
Q3 revenue rose 10.5% YoY to $13.5M, while pulse revenue grew 72% to $5.4M. Nine-month revenue increased 18%, and cash burn fell to $3.2M from $7.7M YoY.
-
Q2 revenue rose 18% YoY to $14.6M, with recurring pulse revenue up 83% to $6M and non-GAAP gross margin of 76.3%. FY2024 operating breakeven excluding stock-based compensation was reaffirmed.
-
Q1 revenue grew 27% YoY to $13.2M, with recurring pulse revenue up 118% to $4.7M. Operating loss narrowed to ~$0.4M, and management expects 2024 operating break-even while expanding Pure Impact and core-market reach.
Fiscal Year 2023
-
Q3 revenue grew 49% YoY, recurring pulse revenue nearly doubled, and operating loss and cash burn declined. Management cited continued growth opportunities in non-invasive aesthetics while preparing for Israel-related disruption and pursuing body applications.
-
Q1 revenue rose 86% YoY to $10.4M, with recurring pulse revenue up 74% and non-GAAP gross margin at 74.1%. Management cited $29M in cash and targeted positive EBITDA and breakeven in Q4 2023, alongside continued expansion.